Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ
Executive Summary
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
You may also be interested in...
Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas
The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.
Another Denosumab Deal For mAbxience In MEA
A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”
Ajinomoto Builds Gene Therapy CDMO Capabilities Through $554m Forge Acquisition
With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.